STING1 and cancer: And the key to the tumor immune killing effect mediated by the STING pathway lies in the secretion of IFN‐I.[6] And SR717 is a mimic of CDN, which can induce the presentation of tumor molecules to the immune system and activate toxic T cells and NK cells within tumors and draining lymph nodes.[7] So, to overcome the aforementioned challenges associated with GBCAs and STING agonists, a Turbo‐charging system‐like GBCA, termed as Turbo S, was designed and constructed for MRI‐guided STING pathway‐activated cancer immunotherapy.